Feedback / Questions
vedolizumab subcutaneous (CLS-001) - Comera Life Sci
https://www.globenewswire.com/news-release/2023/03/16/2628609/0/en/Comera-Life-Sciences-Reports-Financial-Results-for-Fourth-Quarter-and-Full-Year-2022-and-Recent-Business-Highlights.html
Mar 16, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next